title: The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets.
abstract: BACKGROUND
  Cannabinoid receptor agonists reverse nausea and vomiting produced by chemotherapy and radiation therapy in animals and humans but have not been tested against opioid-induced emesis. This study tests the hypothesis that cannabinoid receptor agonists will prevent opioid-induced vomiting.
  
  
  METHODS
  Twelve male ferrets were used. They weighed 1.2-1.6 kg at the beginning and 1.8-2.3 kg at the end of the experiments. All drugs were injected subcutaneously. WIN55,212-2, a mixed CB1-CB2 cannabinoid receptor agonist, was administered 25 min before morphine. Retches and vomits were counted at 5-min intervals for 30 min after morphine injection.
  
  
  RESULTS
  Retching and vomiting responses increased with increasing morphine doses up to 1.0 mg/kg, above which the responses decreased. Previous administration of naloxone prevented morphine-induced retching and vomiting. WIN55,212-2 dose-dependently reduced retching and vomiting. The ED50 was 0.05 mg/kg for retches and 0.03 mg/kg for vomits. At 0.13 mg/kg, retching decreased by 76% and vomiting by 92%. AM251, a CB1 receptor-selective antagonist, blocked the antiemetic actions of WIN55,212-2, but AM630, a CB2 receptor-selective antagonist, did not.
  
  
  CONCLUSIONS
  These results demonstrate that WIN55,212-2 prevents opioid-induced vomiting and suggest that the antiemetic activity of WIN55,212-2 occurs at CB1 receptors. This is consistent with findings that CB1 receptors are the predominant cannabinoid receptors in the central nervous system and that antiemetic effects of cannabinoids appear to be centrally mediated.
authors.affiliation: Department of Anesthesiology, The University of Arizona, Tucson 85724-5114, USA.
authors.forename: I I
authors.initials: II
authors.lastname: Simoneau
authors.forename: M S
authors.initials: MS
authors.lastname: Hamza
authors.forename: H P
authors.initials: HP
authors.lastname: Mata
authors.forename: E M
authors.initials: EM
authors.lastname: Siegel
authors.forename: T W
authors.initials: TW
authors.lastname: Vanderah
authors.forename: F
authors.initials: F
authors.lastname: Porreca
authors.forename: A
authors.initials: A
authors.lastname: Makriyannis
authors.forename: T P
authors.initials: TP
authors.lastname: Malan
mesh_terms: D000701:Analgesics, Opioid / Q000633:toxicity*; D000818:Animals; D000932:Antiemetics / Q000494:pharmacology*; D048588:Benzoxazines; D005289:Ferrets; D008297:Male; D009020:Morphine / Q000633:toxicity*; D009025:Morpholines / Q000494:pharmacology*; D009281:Naphthalenes / Q000494:pharmacology*; D010880:Piperidines / Q000494:pharmacology; D011720:Pyrazoles / Q000494:pharmacology; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug / Q000819:agonists* / Q000502:physiology; D014839:Vomiting / Q000517:prevention & control*
chemical_list: D000701:Analgesics, Opioid; D000932:Antiemetics; D048588:Benzoxazines; D009025:Morpholines; D009281:Naphthalenes; D010880:Piperidines; D011720:Pyrazoles; D043882:Receptors, Cannabinoid; D011955:Receptors, Drug; C103505:AM 251; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D009020:Morphine